Ledger.Open graph →
SEC Form D · filed June 11, 2020

Fulcrum Therapeutics, Inc

Offering
$68.5M
Sold
$68.5M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (27)

Mark Levin · Rockville, MDDirectorJames Geraghty · Cambridge, MADirectorDiego Cadavid · Cambridge, MAExecKate Haviland · Cambridge, MADirectorJames Collins · Cambridge, MADirectorRobert Gould · New York, NYExec · DirectorOwen Wallace · Cambridge, MAExecAlan Ezekowitz · Cambridge, MADirectorTyler Cauble · NASHVILLE, TNDirectorJett Fein · Sacramento, CADirectorDavid J. Blumberg · San Francisco, CAExec · DirectorDhiren Jhaveri · Rosemont, ILExecTaylor S. Barbosa · Morrisville, NCDirectorRamin Karimpour · Morrisville, NCDirectorHalf Moon GP, LLC · Larchmont, NYDirectorKatina Dorton · Cambridge, MADirectorBryan Stuart · CHELSEA, MAExecJake Joraanstad · Fargo, NDDirectorRalf Mehnert-Meland · Fargo, NDDirectorFred Day · Houston, TXDirectorHelen Newell · Houston, TXDirectorPriscilla Hill · Missouri City, TXExec · DirectorRaymond N. Catone · Fort Lauderdale, FLExecAlan Shipnuck · OCEANSIDE, CADirectorDiego Cadavid · Cambridge, MAExecKatina Dorton · Cambridge, MADirectorBryan Stuart · Cambridge, MAExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗